GlassScriptPhysician profile
Joseph H Munning
NPI 1427016336
$1,960.46
in general payments reported to CMS, 2019-2025
27 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.10 · 2020: $32.11 · 2021: $288 · 2022: $243 · 2023: $367 · 2024: $618 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $326.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $184.89 | 2021-2025 | |
| Pfizer INC. | $106.79 | 2022-2025 | |
| Abbott Laboratories | $88.51 | 2021-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $88.12 | 2020-2024 | Yupelri |
| Glaxosmithkline, LLC. | $68.93 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biogen, INC. | $51.45 | 2021-2025 | Zurzuvae |
| Exact Sciences Corporation | $48.52 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $41.80 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.37 | 2025 | Caplyta |
| Amgen INC. | $35.48 | 2023-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $30.57 | 2023-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Kowa Pharmaceuticals America, INC. | $29.38 | 2024-2025 | Zoryve |
| Nevro Corp. | $26.05 | 2024 | Senza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $23.52 | 2024 | Crysvita |
| Axsome Therapeutics, INC. | $19.46 | 2025 | Auvelity |
| Medtronic, INC. | $18.73 | 2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $16.15 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $15.10 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.03 | 2023 | Givlaari |
| Boston Scientific Corporation | $14.64 | 2019 | |
| Esperion Therapeutics, INC. | $14.51 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.06 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $13.64 | 2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $13.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Munning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.